tradingkey.logo
tradingkey.logo
Search

Organon & Co

OGN
Add to Watchlist
13.475USD
+0.025+0.19%
Close 06/24, 16:00ETQuotes delayed by 15 min
3.50BMarket Cap
14.27P/E TTM

TradingKey Stock Score of Organon & Co

Currency: USD Updated: 2026-06-23

Key Insights

Organon & Co's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 10.80.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Organon & Co's Score

Industry at a Glance

Industry Ranking
80 / 157
Overall Ranking
187 / 4573
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Organon & Co Highlights

StrengthsRisks
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 34.38%.
Overvalued
The company’s latest PE is 14.25, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 239.27M shares, decreasing 1.64% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 2.48M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.41.

Analyst Rating

Based on 6 analysts
Hold
Current Rating
10.800
Target Price
-19.58%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Organon & Co?

The TradingKey Stock Score provides a comprehensive assessment of Organon & Co based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Organon & Co’s performance and outlook.

How do we generate the financial health score of Organon & Co?

To generate the financial health score of Organon & Co, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Organon & Co's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Organon & Co.

How do we generate the company valuation score of Organon & Co?

To generate the company valuation score of Organon & Co, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Organon & Co’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Organon & Co’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Organon & Co.

How do we generate the earnings forecast score of Organon & Co?

To calculate the earnings forecast score of Organon & Co, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Organon & Co’s future.

How do we generate the price momentum score of Organon & Co?

When generating the price momentum score for Organon & Co, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Organon & Co’s prices. A higher score indicates a more stable short-term price trend for Organon & Co.

How do we generate the institutional confidence score of Organon & Co?

To generate the institutional confidence score of Organon & Co, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Organon & Co’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Organon & Co.

How do we generate the risk management score of Organon & Co?

To assess the risk management score of Organon & Co, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Organon & Co’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Organon & Co.
KeyAI